Loading…
Stem Cell Therapeutic and Research Reauthorization Act of 2019
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
51pct
1d open
vs 9,062 other HR bills in the 116th — cohort avg 39d
Stem Cell Therapeutic and Research Reauthorization Act of 2019 This bill modifies and reauthorizes through FY2024 the C.W. Bill Young Cell Transplantation Program, which provides support to patients who need a potentially life-saving bone marrow transplant or umbilical cord blood transplant. It also reauthorizes through FY2024 the Stem Cell Therapeutic and Research Act of 2005, which provides for the collection and maintenance of new units of high-quality cord blood. The bill requires the Advisory Council on Blood Stem Cell Transplantation to convene at least twice per calendar year.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2019 · fourth_quarter · Health Issues
Reauthorization of the CW Bill Young Cell Transplantation Program and National Cord Blood Inventory; H.R. 3520 "Stem Cell Therapeutic and Research Reauthorization Act of 2019"; regenerative medicine issues; H.R. 4764, the TRANSPLANT Act
Client expense: Not reported · Firm income: $69,000
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2019 · third_quarter · Health Issues
Reauthorization of the CW Bill Young Cell Transplantation Program and National Cord Blood Inventory; H.R. 3520 "Stem Cell Therapeutic and Research Reauthorization Act of 2019"; regenerative medicine issues
Client expense: Not reported · Firm income: $69,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2019 · second_quarter · Health Issues
Reauthorization of the CW Bill Young Cell Transplantation Program and National Cord Blood Inventory; H.R. 3520 "Stem Cell Therapeutic and Research Reauthorization Act of 2019"; regenerative medicine issues
Client expense: Not reported · Firm income: $69,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE